Seroprevalence of anti-HBs antibodies at young adulthood, before and after a booster vaccine dose, among medical personnel vaccinated in infancy

Hartal, Michael; Yavnai, Nirit; Galor, Inbal; Avramovich, Eva; Sela, Tamar; Kayouf, R.; Tzurel-Ferber, Anat; Greenberg, Lior J.; Halperin, Tami; Levine, Hagai

doi:10.1016/j.vaccine.2015.07.058

Cited by 11 publications

(14 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to a Taiwanese study conducted in 2010, there was a lack of anamnestic responses in 25% of college freshmen, which was followed by a report that more than 90% of total subjects achieved a seroconversion from seronegative to seropositive status after completing a 2-dose booster vaccination (35). According to another study conducted in medical personnel from Israel, the rate of anti-HBs seropositivity was 33.7% at baseline, 87.7% after the first booster vaccination and 97.9% at one month of the second one (36). …”

Section: Discussionmentioning

confidence: 99%

A Single Center Analysis of the Positivity of Hepatitis B Antibody after Neonatal Vaccination Program in Korea

Kim

Hong

et al. 2017

J Korean Med Sci

View full text Add to dashboard Cite

The antibody to hepatitis B surface antigen (anti-HBs) seropositivity rate after 3 doses of hepatitis B virus (HBV) vaccination during infancy period is known to be higher than 90%. However, a considerable number of vaccines do not form protective anti-HBs or chronologic decrease of anti-HBs. We retrospectively collected data of HBV serologic test results in 20,738 individuals from 2000 to 2015. After exclusion criteria were applied, 19,072 individuals were included. We analyzed the anti-HBs seropositivity rate, anti-HBs disappearance rate, anti-HBs positive seroconversion rate after receiving a booster vaccine, and the difference in anti-HBs positivity between the 2 groups; group A (born before 2005, while both recombinant vaccines and plasma-derived vaccines were used) and group B (born after 2005, when only recombinant vaccines were used by national regulation). The anti-HBs seropositivity rate was 55.8%, but there was a significant difference in the rate of seropositivity for anti-HBs between the group A and B (53.0% vs. 78.1%, P < 0.001). There was no significant age-adjusted difference in the mean seropositivity rate between the 2 groups (P = 0.058). In addition, the anti-HBs positivity rate was significantly lower in the group A as compared with the group B during infancy (83.1% vs. 92.1%, P < 0.001). A total of 1,106 anti-HBs-positive subjects underwent serologic tests more than twice. Of these, 217 subjects (19.6%) showed anti-HBs disappearance. After booster vaccinations, 87.4% (83/95) achieved seroconversion from seronegative to seropositive. Our results highlight the importance of lifelong protection against HBV and the possible necessity of booster vaccination after adolescent period.

show abstract

Section: Discussionmentioning

confidence: 99%

A Single Center Analysis of the Positivity of Hepatitis B Antibody after Neonatal Vaccination Program in Korea

Kim

Hong

et al. 2017

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…22 HBV surface antibody (HBsAb) levels wane over time in a large percentage of people vaccinated over 10 years previously; anamnestic responses to vaccine boosters in this population indicate that once established, immune memory is preserved. [23][24][25] Routine boosters are not necessary.…”

Section: Hepatitis B Vaccinementioning

confidence: 99%

Vaccines for Health Care Personnel

Swift

Behrman²

2019

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Medical Center Occupational Health (MCOH) programs must protect health care personnel (HCP) against the occupational risk of vaccine-preventable diseases. This thematic review outlines the rationale for the use of recommended vaccines in HCP; summarizes the available evidence regarding vaccine effectiveness, administration, and assessment of immunity; and provides guidance for MCOH programs navigating challenging situations.

show abstract

“…137 Moreover, HCWs are recommended to receive 3 doses of HBV vaccine at 0, 1, and 6 months if there is no documentation of prior HBV vaccination (complete 3-dose vaccine series) or if there is no serologic evidence of immunity. 138 HCWs should be tested for HBV surface antibody (anti-HBs) 1-2 months after the third dose to document immunity. 138 HCWs whose antiHBs are less than 10 mIU/mL should be re-vaccinated with a second 3-dose series.…”

Section: Vaccination Of Health Care Workers (Hcws)mentioning

confidence: 99%

“…138 HCWs should be tested for HBV surface antibody (anti-HBs) 1-2 months after the third dose to document immunity. 138 HCWs whose antiHBs are less than 10 mIU/mL should be re-vaccinated with a second 3-dose series. Non-responders (i.e., those in whom antiHBs remains less than 10 mIU/mL after the second 3-dose series) should be considered susceptible to HBV and should be counselled regarding precautions to prevent HBV infection and the need to obtain HBV immunoglobulin prophylaxis for any known or probable parenteral exposure to HBs antigen (HBsAg-positive blood or blood from an individual with an unknown HBsAg status).…”

Section: Vaccination Of Health Care Workers (Hcws)mentioning

confidence: 99%

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)

Esposito

Bonanni

Maggi

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rapid population aging has become a major challenge in the industrialized world and progressive aging is a key reason for making improvement in vaccination a cornerstone of public health strategy. An increase in age-related disorders and conditions is likely to be seen in the near future, and these are risk factors for the occurrence of a number of vaccine-preventable diseases. An improvement in infectious diseases prevention specifically aimed at adults and the elderly can therefore also decrease the burden of these chronic conditions by reducing morbidity, disability, hospital admissions, health costs, mortality rates and, perhaps most importantly, by improving the quality of life. Among adults, it is necessary to identify groups at increased risk of vaccine-preventable diseases and highlight the epidemiological impact and benefits of vaccinations using an evidence-based approach. This document provides clinical practice guidance on immunization for adults in order to provide recommendations for decision makers and healthcare workers in Europe. Although immunization is considered one of the most impactful and cost-effective public health measures that can be undertaken, vaccination coverage rates among adults are largely lower than the stated goal of 95% among adults, and stronger efforts are needed to increase coverage in this population. Active surveillance of adult vaccine-preventable diseases, determining the effectiveness of the vaccines approved for marketing in the last 5 y, the efficacy and safety of vaccines in immunocompromised patients, as well as in pregnant women, represent the priorities for future research.

show abstract

Seroprevalence of anti-HBs antibodies at young adulthood, before and after a booster vaccine dose, among medical personnel vaccinated in infancy

Cited by 11 publications

References 34 publications

A Single Center Analysis of the Positivity of Hepatitis B Antibody after Neonatal Vaccination Program in Korea

A Single Center Analysis of the Positivity of Hepatitis B Antibody after Neonatal Vaccination Program in Korea

Vaccines for Health Care Personnel

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)

Contact Info

Product

Resources

About